

# Combination Immunotherapy Targeting Melanoma

NCT06739226

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Shenzhen Geno-Immune Medical Institute
<b>Enrollment</b>	30 participants

## Plain Language Summary

---

This study tests a combination immunotherapy approach for advanced melanoma (skin cancer) in patients whose disease progressed after standard first-line treatment. The therapy targets proteins specific to melanoma cells using the immune system.

**\*\*You may be eligible if...\*\***

- You have been diagnosed with non-removable, metastatic, or recurring melanoma
- You have already received standard first-line therapy
- Your tumor has been confirmed to express melanoma-specific proteins by lab testing
- You weigh at least 40 kg and are between 18 and 75 years old
- You have a life expectancy of at least 8 weeks

**\*\*You may NOT be eligible if...\*\***

- You have not previously tried standard melanoma therapy
- Your tumor does not express the required melanoma proteins
- Your overall health or organ function does not meet study requirements

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (19)

- Patients with melanoma have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions.
- The expression of melanoma specific antigens is immunohistochemically stained and verified.
- Body weight greater than or equal to 40 kg.
- Age: e18 year and d 75 years of age at the time of enrollment.
- Life expectancy: at least 8 weeks.

... and 14 more (see full listing online)

### Exclusion (8)

- Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity.
- Untreated central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 4 weeks following completion of therapy are eligible.
- Previous treatment with other genetically engineered CAR T cells.
- Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.
- Patients who require systemic corticosteroid or other immunosuppressive therapy.

... and 3 more (see full listing online)

---

<https://clinicaltrials.gov/ct2/show/study/NCT06739226>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

---

<https://clinicaltrials.gov/study/NCT06739226>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).